Femeda is a UK based company focused on developing a range technically ground breaking medical devices for female urinary incontinence. 698 million women worldwide are affected by incontinence, yet many existing products focus on managing and treating the symptoms of urinary incontinence, rather than the underlying cause.
Femeda is focused on the launch of Pelviva™, a unique patented disposable medical device for the treatment of female incontinence. Pelviva™, uses reactive pulse technology to strengthen weak pelvic floor muscles to prevent leaks and control urge incontinence. Pelviva™ has been shown to clinically improve bladder control in 84% of women after 12 weeks of treatment.
The Company initiated a soft launch under the Pelviva brand in August 2014. The Company is planning to recruit 6,700 trial users and have circa 1,500 loyal customers by the middle of 2015. The targeted exit is at £30m+ within 18 months with targeted buyers including Procter & Gamble UK; SCA; Reckitt Benckiser and Ontex Global.